Sun Pharmaceutical Industries Limited (Sun Pharma) has achieved a 52-week high, with its stock price rising to ₹1,781.55 per share on August 23, 2024. This surge follows the company’s recent announcement regarding the launch of its new drug, Starzio, which is designed to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Starzio, the brand name for Tedizolid Phosphate, marks a significant advancement in antibiotic treatment. It is an oxazolidinone-class antibiotic that offers a once-daily oral dosing regimen for six days, contrasting sharply with the conventional treatment which involves twice-daily doses over 10 to 14 days. This new drug is effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and simplifies treatment by requiring no dose adjustments for elderly patients or those with liver or kidney impairments.
Kirti Ganorkar, CEO of India Business at Sun Pharma, emphasized the impact of Starzio on addressing drug-resistant bacterial infections. “Drug-resistant bacteria such as MRSA are increasingly difficult to treat due to the limited availability of effective treatment options. With Starzio, we introduce a highly effective treatment with the convenience of once-a-day dosing,” Ganorkar said.
The launch of Starzio addresses a significant medical need, as skin and soft tissue infections are common in India, constituting approximately 29-32 percent of all infections, often complicated by conditions such as diabetes and renal or hepatic dysfunction.
Sun Pharma has secured licensing rights from Merck Sharp & Dohme Singapore Trading Pte. Ltd. to develop, manufacture, and market Tedizolid Phosphate in India. This move highlights Sun Pharma’s commitment to expanding its therapeutic offerings and responding to critical healthcare needs.
As of 2:39 PM, Sun Pharma’s stock was trading 1.45 percent higher at ₹1,776 per share. The company’s market capitalization stands at ₹4,20,015.51 crore, according to the Bombay Stock Exchange (BSE). This rise in share value contrasts with the BSE Sensex, which was up by 0.07 percent at 81,112.27 levels.
With the successful launch of Starzio, Sun Pharma continues to reinforce its position as a leader in the pharmaceutical industry, both in India and globally, where it maintains a strong presence in key markets including the United States and Europe. The company’s diversified portfolio spans therapeutic areas such as psychiatry, neurology, cardiology, orthopaedics, ophthalmology, dermatology, gastroenterology, and oncology.
hii Aditi Sahu this side..
As an author and writer specializing in investment and finance , I am dedicated to delivering insightful articles and news stories that inform and engage the investment community . My focus is on providing timely and relevant content that covers market trends , innovative strategies , and key financial development . My goal is to equip investors with the knowledge and insights needed to make informed decisions and succeed in a dynamic financial environment.
